Participated · Series C · Mar 2022

OnePredict is a South Korea–based industrial AI company that provides predictive maintenance and asset-diagnostic software. Its flagship GuardiOne® digital twin uses proprietary algorithms to deliver high-accuracy health diagnoses and predict failures for key industrial facilities. The company serves customers across high-tech manufacturing, energy generation, petrochemicals, and utilities. Founded in 2016 by Byung‑Dong Yoon, OnePredict has secured top-tier domestic customers and is a leader in South Korea’s industrial AI sector. In March 2022 it closed a $25.0M (KRW 30 billion) Series C to strengthen its domestic position and support global expansion. The company plans to use the funding to advance its solutions and establish global partnerships in North America, the Middle East, and Southeast Asia.

Participated · Series A · Feb 2022

Soelect is a North Carolina battery-technology startup that develops fast charge-capable anode materials and technologies aimed at enabling the next generation of EV batteries. The company closed an $11 million Series A to scale its anode technologies. It intends to use the capital to scale manufacturing and development of its fast charge-capable anodes. The startup's anode tech is positioned as a potential enabler for both lithium-metal and solid-state EV battery anode designs. GM Ventures joined the round as a strategic investor alongside lead investor Lotte Chemical and KTB Network, indicating potential OEM interest and pathways to vehicle or manufacturing integration. The article does not disclose revenue, users, or other operating metrics.

Participated · Series B · Jan 2022

Virnect develops industrial XR solutions, including remote collaboration, facility digitalization and monitoring, built on its in-house AR‑SDK core technology. The company operates research centers in Austria and Korea and has completed over 100 projects. Its deployments include customers such as LG Chemical, Samsung Electronics, 39 corporate subsidiaries, and 27 public-sector organizations including KAC and KEPCO. Virnect holds 107 intellectual property rights and has won 36 awards for product performance. With the new funding, it plans to expand its industrial XR ecosystem, recruit talent, develop differentiated products, and increase global marketing efforts. An IPO on the KOSDAQ exchange is expected this year.

Participated · Series A · Sep 2021

GenEdit is a US genetic medicines developer focused on hydrophilic nanoparticles (HNPs) for nucleic acid‑based therapies. The company’s core product is HNPs designed to enable delivery of nucleic acid‑based medicines for autoimmune indications. GenEdit announced a multiyear collaboration and license agreement with Genentech to discover and develop these nanoparticles for autoimmune targets. Under the agreement, Genentech will be responsible for pre‑clinical, clinical, and regulatory development as well as commercialization of products resulting from the use of GenEdit’s nanoparticles. GenEdit also completed a $24 million Series A1 financing round. The partnership with a major biotech subsidiary positions GenEdit to leverage Genentech’s development and commercialization capabilities to advance its platform. GenEdit is a biotechnology company developing curative therapies through targeted in vivo delivery of genetic medicines using its NanoGalaxy platform of non-viral, non-lipid polymer nanoparticles. The platform is designed to deliver DNA, RNA, or CRISPR ribonucleoprotein to add, delete, edit, or silence genes for therapeutic effect. NanoGalaxy comprises thousands of chemically distinct polymers engineered to target different tissues and cell types. GenEdit is developing an internal pipeline and also delivers payloads for partner programs, with plans to select therapeutic candidates for clinical development targeting diseases of the nervous system. The company disclosed in vivo data showing tissue-selective delivery after intravenous or intrathecal administration and that nanoparticles can be dosed multiple times while preserving payload activity. GenEdit is based in South San Francisco, California. GenEdit, Inc. is a Berkeley, CA–based developer of a proprietary polymer nanoparticle technology platform for non-viral delivery of gene therapeutics. Launched in 2016 by UC Berkeley scientists Kunwoo Lee, Hyo Min Park, and Niren Murthy, the company has developed a polymer nanoparticle library and established initial proof of concept by delivering CRISPR-Cas9 and gene editors to target tissues. Its proprietary nanoparticles have broad applicability, including the development of CRISPR-based therapeutics and gene therapy products for a wide range of genetic diseases. GenEdit completed an $8.5M seed financing and intends to use the funds to continue to build and advance its polymer nanoparticle system. The round reflects participation from both new and pre-seed investors, and included board additions tied to the financing.

Participated · Series B · Apr 2021

PharmCADD develops an AI- and physics-based drug discovery platform called Pharmulator™, which integrates protein 3D structure prediction, molecular dynamics, quantum calculation, toxicity prediction and AI drug generation. The platform is used to generate novel synthetic small molecules and to support work in PROTACs, mRNA vaccines and drug delivery systems. PharmCADD reports a co-developed mRNA COVID-19 vaccine with Eyegene that demonstrated neutral antibody titers similar to the Moderna vaccine. The company employs about 50 people, including 34 R&D staff and 17 Ph.D.s. The Series B proceeds will be used to advance Pharmulator™, expand R&D headcount, and fund preclinical studies of internal pipelines. PharmCADD also plans to expand internationally by launching U.S. and India branches.